Cost-effectiveness of fingolimod versus interferon-β1a for the treatment of pediatric-onset multiple sclerosis in Canada.

Hamid Reza Nakhaipour Umakanth Vudumula Vivek Khurana Guillaume Sébire Jean K Mah Daniela Pohl Robyn Schecter Nicholas Adlard

Published in: Journal of medical economics (2020)

Fingolimod is cost effective compared with IFN β-1a for the treatment of POMS over a time horizon of two years representing patients followed up to a mean age of 18 years in Canada.

Keyphrases

multiple sclerosis
end stage renal disease
dendritic cells
newly diagnosed
chronic kidney disease
white matter
young adults